Bristol Myers Squibb’s recently acquired schizophrenia drug demonstrated persistent symptom improvement without patients gaining weight, according to new long-term data, bolstering excitement around ...
Bristol Myers Squibb and Johnson & Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.
BioNTech and its new partner Bristol Myers Squibb have trotted out the first global data for their PD-L1xVEGF bispecific in small cell lung cancer, results BioNTech’s chief medical officer, Özlem ...
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an FDA nod to be used alongside chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results